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Objective: Several attributes of female reproductive history, including age at natural menopause (ANM), have
been related to primary open-angle glaucoma (POAG). We assembled 18 previously reported common genetic
variants that predict ANM to determine their association with ANM or POAG.
Methods: Using data from the Nurses’ Health Study (7,143 women), we validated the ANM weighted
genetic risk score in relation to self-reported ANM. Subsequently, to assess the relation with POAG, we
used data from 2,160 female POAG cases and 29,110 controls in the National Eye Institute Glaucoma
Human Genetics Collaboration Heritable Overall Operational Database (NEIGHBORHOOD), which consists of
8 datasets with imputed genotypes to 5.6þmillion markers. Associations with POAG were assessed in each dataset,
and site-specific results were meta-analyzed using the inverse weighted variance method.
Results: The genetic risk score was associated with self-reported ANM (P¼ 2.2 10–77) and predicted
4.8% of the variance in ANM. The ANM genetic risk score was not associated with POAG (Odds
Ratio (OR)¼ 1.002; 95% Confidence Interval (CI): 0.998, 1.007; P¼ 0.28). No single genetic variant
in the panel achieved nominal association with POAG (P 0.20). Compared to the middle 80 percent,uary 15, 2016; revised and accepted July 18, 2016.
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there was also no association with the lowest 10th percentile or highest 90th percentile of genetic risk score
MENOPAUSE GENETIC RISK SCORE AND GLAUCOMAwith POAG (OR¼ 0.75; 95% CI: 0.47, 1.21; P¼ 0.23 and OR¼ 1.10; 95% CI: 0.72, 1.69; P¼ 0.65,
respectively).
Conclusions: A genetic risk score predicting 4.8% of ANM variation was not related to POAG; thus, genetic
determinants of ANM are unlikely to explain the previously reported association between the two phenotypes.
Key Words: Age at natural menopause – Genetic risk score – Primary open-angle glaucoma.
ry open-angle glaucoma (POAG) is an optic We validated the predictive ability of a previously pub-P
rima
neuropathy strongly influenced by age and intraocular
pressure that is a leading cause of irreversible blind-
ness worldwide.1 Women carry a higher burden of visual
disability related to POAG, presumably because they live
longer than men.2 Although women are not necessarily more
predisposed to POAG than men, attributes of female repro-
ductive history linked to circulating estrogen levels are related
to this disease. Later age at menarche,3,4 oral contraceptive
use,4,5 early oophorectomy,6 and earlier age at menopause7,8
are associated with an increased risk of POAG. In contrast,
later age at menopause9 and postmenopausal hormone
use10,11 were associated with reduced risk of POAG. Inter-
estingly, post hoc analysis of a randomized clinical trial in the
Women’s Health Initiative revealed that postmenopausal
estrogen use was associated with a modest 0.5mm Hg
reduction in intraocular pressure,12 the only known modifi-
able risk factor for POAG.
Early menopause is associated with several nonocular
diseases.13,14 With respect to glaucoma, in the Rotterdam
Study, enteringmenopause before age 45was associatedwith
a 2.6-fold increased risk of open-angle glaucoma compared
to entering menopause after age 50.7 Among participants
65 years or older in the Nurses’ Health Study, entering
menopause at age 54 years or older was associated with a
47% reduced risk of high-tension POAG compared to enter-
ing menopause between the ages of 50 to 54.9 To better
understand these results, we evaluated whether this relation-
ship with POAG may be mediated by age at natural meno-
pause (ANM) genetic biomarkers, because ANM is a highly
heritable trait.15-18 Recently, several common genetic var-
iants that predict menopause, a critical step in ovarian aging,
have been identified.19 These variants do not overlap with the
variants responsible for estrogen metabolism that we pre-
viously reported to be associated with POAG among
women20; nor do they overlap with known common gene
variants for POAG.21 The nonoverlap between gene variants
related toANMandPOAGcould reflect the fact that genome-
wide significant loci for these traits represent variants with
the most stringent P values to reduce false discovery from
multiple comparisons. ANM gene variants could represent
novel biologically relevant POAG loci with associations that
may have been obscured by the use of stringent P values.
Assembling ANM gene variants in a panel enhances
the power to detect an overall association between ANM
genetic variants and POAG while averting the multiple
comparisons problem.lished ANM genetic panel19 in relation to self-reported ANM
in the Nurses Health Study and then determined the associ-
ation with POAG in a large United States case-control dataset,
composed of European-Americans referred to as the National
Eye Institute Glaucoma Human Genetics Collaboration
Heritable Overall Operational Database (NEIGHBORHOOD).
METHODS
The nurses health study and the national eye institute
glaucoma human collaboration heritable overall
operational database
The nurses health study (NHS) includes more than 121,000
female nurse participants who answered biennial question-
naires since cohort inception in 1976, including questions on
reproductive status and various diseases such as glaucoma.22
Out of a subset of 11,522 women genotyped on three different
high throughput platforms (various generation Illumina arrays
specified below, the Illumina OmniExpress and the Affyme-
trix 6.0 arrays) for 11 disease endpoints, 7,143 had data on
ANM and were included in the assessment of the relation
between self-reported ANM and genetic risk score for ANM
(discussed below). Women with no data on age at menopause
or those with surgical menopause, history of pelvic radiation
or menopause of unknown type were excluded. Data on
menopause status in Nurses’ Health Study has been pre-
viously validated.23
The national eye institute glaucoma human collaboration
heritable overall operational database (NEIGHBORHOOD)
dataset represents a genome-wide meta-analysis summary
dataset from eight independent studies, including the Nurses’
Health Study, with a total of 3,853 POAG cases and 33,480
controls of European ancestry from the United States. Details
regarding the composition of the dataset used can be found in
the study by Cooke Bailey et al24 and in Supplemental
Table 1, Supplemental Digital Content 1, http://links.
lww.com/MENO/A180. A harmonized definition of POAG
across these datasets consisted of the following features: open
ocular anterior segment angles, pathologic cupping (cup-disc
ratio 0.7 in both eyes or inter-eye cup-disc ratio difference
 0.2), or at least one reliable visual field with deficits
localizing to the optic nerve without secondary cause;
although elevated intraocular pressure was not a criterion
for POAG definition, if present, there had to be no secondary
causes on anterior segment examination. We used the female-
only meta-analyzed data in the NEIGHBORHOOD dataset
from 2,160 POAG cases and 29,110 controls. This datasetMenopause, Vol. 24, No. 2, 2017 151
partially overlapped with the NHS dataset used to assess the signifying two alleles. The ANM genetic risk score was
PASQUALE ET ALrelation between ANM genetic risk score and self-reported
ANM. From the Nurses’ Health Study, we included 76 POAG
cases and 2,488 controls who were genotyped on the Affy-
metrix 6.0 platform and 259 POAG cases and 1,367 controls
who were genotyped on various generation Illumina platforms
(317K, 550K, 610K, and the 660W arrays); controls who did
not report an eye exam were not included in the
POAG analyses.
Formation of the age at natural menopause weighted
genetic risk score
The largest genome-wide meta-analysis of ANM included
53,403 women of European descent19 and identified 19 gene
variants that were associated with ANM at the genome-wide
significance level. Among the 19 gene variants associated
with ANM reported by Stolk et al,19 18 were available in the
Nurses Health Study and served as the basis for the ANM
genetic risk score in our primary analysis. We also formed a
larger genetic panel containing 44 common gene variants
derived from a genome-wide scan of 69,360 women of
European ancestry25 and present data related to this panel
in Supplemental Table 2, Supplemental Digital Content 2,
http://links.lww.com/MENO/A181, as these results did not
differ from our primary analysis. To evaluate the relationship
between ANM genetic risk score and self-reported ANM,
genotypes were derived from the merged datasets in Nurses’
Health Study described above. Details regarding how these
datasets were merged are available in the supplemental
material of the study by Cooke Bailey et al.24 Briefly, we
created three platform-specific datasets (one each for earlier
generation Illumina arrays, the Illumina OmniExpress array
and the Affymetrix 6.0 array) and imputed the datasets using
the 1,000 genomes phase I release. Each dataset underwent
extensive quality control measures including analyses within
and across the platforms to exclude duplicate samples and
related individuals. To decrease false positives in imputation,
we used only gene variants that overlap when combining all
the datasets. The details of the quality control process used in
imputing across platforms have been previously published.26
Gene variants that would create spurious associations and
gene variants with poor imputation quality score at most 0.3 as
determined by the MaCH software package designed to infer
genotypes at un-typed loci were excluded.
For the NEIGHBORHOOD dataset, we used the meta-
analysis results of POAG in women only. Details regarding
the composition of the eight NEIGHBORHOOD datasets,
genotyping, quality control measures, imputation and meta-
analysis can be found in Cooke Bailey et al.24
Statistical analyses
To model ANM and POAG, we used multivariable linear
regression and logistic regression, respectively. Individual
gene variants were coded for the minor allele dosage associ-
ated with later-onset of ANM based on their imputation score
with values ranging from zero for no alleles up to two,
152 Menopause, Vol. 24, No. 2, 2017defined as weighted based on the effect estimate of each
gene variant or unweighted, where each gene variant carried
equal weight.
In analyses for ANM, we used platform-specific results
from the Nurses Health Study and meta-analyzed them with a
computational tool called METAL,27 after ruling out hetero-
geneity with the Cochran Q-statistic. We adjusted for age in
the year 1986, eigenvectors, and 11 disease endpoints includ-
ing POAG (as genome-wide data in Nurses’ Health Study was
intended to assess other outcomes including coronary heart
disease, type 2 diabetes, pancreatic cancer, kidney stones,
glioma, colon cancer, gout, endometrial cancer, mammo-
graphic density, and ovarian cancer) in multivariate analyses.
In analyses for POAG, we used an inverse-variance
weighted sum meta-analysis of individual SNP effect esti-
mates from the female-only analysis, as proposed by
Aschard.28 Let b¼ (bG1, bG2, . . . bGm), a vector of elements
of bGm, which represents the reported effect of the mth
selected gene variant on POAG in the meta-analysis summary
statistics and s2bGi
represent the variance of each estimate.
Under the assumption of independence between the gene
variants (ie, assuming the gene variants’ inter-correlations
are negligible), x2GRS, the chi-squared for the GRS effect on
POAG, can be derived as:
x2GRS ¼
P
m
wi bGi
s2
bGi
 2
P
m
w2i
s2
bGi
We adjusted for age in years as a linear variable at DNA
collection for POAG cases and controls as well as site-specific
eigenvectors. To allow for differences in effect among the
individuals with extreme values for the genetic risk score, we
also considered a model to assess the relation between scores
in the less than 10th percentile and more than 90th percentile
relative to the middle 80% of genetic risk scores.
RESULTS
Mean ANM in the Nurses’ Health Study sample was
50.6 years (standard deviation¼ 3.6 y). Age differences
between cases and controls were adjusted for in genetic
associations with POAG.
Age at natural menopause genetic variants in relation to
self-reported ANM in the nurses’ health study
Various studies have reported that between 2.5% to 4.1% of
the reported total variance of ANM was explained by genes
listed in Table 1.19 We first tested each variant for association
with self-reported ANM in the Nurses’ Health Study using
standard univariate linear regression. Almost all were nom-
inally significant (16 of 18) and all showed positive corre-
lation with reported ANM, in agreement with their previously
reported effects (Table 1).19 The weighted gene risk score was
1.19 (Table 1) and the most significant gene locus was
rs11668344 (TMEM150B; P¼ 3.9 1020). When all were
 2016 The Author(s)
simultaneously included in a multivariate model, these 18 showed nominal association with POAG (P¼ 0.014) but the
MENOPAUSE GENETIC RISK SCORE AND GLAUCOMAgene loci jointly explained 4.8% of the variance of ANM in
Nurses’ Health Study, a slightly larger amount than reported in
Stolk et al.19 The association between either the unweighted or
weighted genetic risk scores and self-reportedANMwas highly
significant with P values of 1.2 10–61 and 2.2 10–77,
respectively. A 1.5-year difference in ANM between women
at the 5th percentile (ANM¼ 49.0 y) and the 95th percentile
(ANM¼ 50.5 y) of the genetic risk score was observed.
Age at menopause gene variants in relation to primary
open-angle glaucoma in the NEIGHBORHOOD dataset
We tested the association between the 18 ANM gene
variants and POAG in the NEIGHBORHOOD dataset using
the summary statistics from the female-specific portion
genome wide scan but no single locus showed even nominal
associations with POAG (P 0.20; Table 2). We then tested
the effect of either the unweighted or the weighted genetic risk
score on POAG, first treating these scores as continuous
variables, and subsequently, allowing for differences in
effect among the individuals with extreme values. Neither
the un-weighted genetic risk score (odds ratio (OR)¼ 1.013;
95% confidence interval (CI): 0.990, 1.036), nor the weighted
score (OR¼ 1.002; 95% CI: 0.998, 1.007) was associated
with POAG. The lowest 10th and highest 90th percentiles
of the weighted genetic risk scores were also not associated
with POAG (OR¼ 0.75; 95% CI: 0.47, 1.21; P¼ 0.23 and
OR¼ 1.10; 95% CI: 0.72, 1.69; P¼ 0.65, respectively). For
the larger 44-member weighted and unweighted ANM
genetic risk scores, we found identical null associations with
POAG; the P values were 0.42 and 0.87, respectively (Supple-
mental Table 2, Supplemental Digital Content 2, http://links.
lww.com/MENO/A181). Only a PIWIL1 locus (rs12824058)TABLE 1. ANM single nucleotide polymorphisms in relation to
SNP chr Gene
SNP analysis
rs4246511 1 RHBDL2
rs1635501 1 EXO1
rs2303369 2 FNDC4
rs10183486 2 TLK1
rs4693089 4 HELQ
rs890835 5 RNF44
rs365132 5 UIMC1
rs2153157 6 SYCP2L
rs2517388 8 ASH2L
rs12294104 11 near MPPED2 C11orf46
rs2277339 12 PRIM1
rs3736830 13 KPNA3
rs4886238 13 TDRD3
rs2307449 15 POLG
rs10852344 16 near TNFRSF17 RUNDC2A, GSPT1
rs11668344 19 TMEM150B
rs12461110 19 NLRP11
rs16991615 20 MCM8
GRS-based analysisa
GRS
wGRS
ANM, Age at natural menopause; GRS, Genetic Risk Score; SNP, single nucleo
aGRS corresponds to the sum of all risk alleles; wGRS corresponds to the weig
coefficient of each SNP from Stolk et al.19 A0/A1 corresponds to the referenceOR was in the opposite direction than expected (1.12) given
the variant allele was associated with later ANM.
DISCUSSION
The ANM GRS panel was significantly predictive of self-
reported ANM in the NHS, although it only explained 4.8% of
the variance of ANM. This finding is consistent with previous
reports in populations of varying ethnicities.29,30 Interest-
ingly, although a few ANM genes are directly implicated
in ovarian function,31,32 many are implicated in DNA repair
mechanisms.25 Although our reported relation between ANM
gene variants and self-reported ANM may be somewhat
inflated due to the 8% overlap between Nurses’ Health Study
and Stolk et al19 they do serve to validate the biomarker panel
as reflective of ANM.
We did not observe associations between the ANM genetic
risk score and POAG, even when we considered the extremes
of the score. Furthermore, none of the gene variants in the
ANM panel were even marginally associated with POAG. It is
unlikely that the sample was underpowered to find an associ-
ation. With the large sample size of 2,160 cases and 29,110
controls in NEIGHBORHOOD, we had 80% power to detect
an OR of 0.94 or lower for association between the ANM gene
panel with POAG. Power dropped to 50% for an OR of 0.96.
We leveraged high throughput genetic data in the largest
POAG case-control set currently available in the form of a
Mendelian randomization experiment. We used panels of
genetic markers that predict ANM in relation to POAG.
Agnostic search mechanisms reveal that many of these genes
work through DNA repair mechanisms, involving enzymes
such asHELQ and POLG, a DNA helicase and DNA polymer-
ase respectively, both of which are strongly associated withself-reported ANM in the Nurses’ Health Study (n¼ 7,143)
A0/A1 Reported effect Beta P
T/C 0.24 0.315 6.5 106
T/C 0.16 0.261 3.3 105
C/T 0.18 0.259 4.5 105
C/T 0.20 0.161 0.012
G/A 0.23 0.296 1.7 106
A/C 0.18 0.159 0.10
T/G 0.29 0.274 5.2 106
A/G 0.17 0.228 2.0 104
G/T 0.26 0.254 2.5 103
T/C 0.23 0.159 0.054
T/G 0.38 0.481 6.9 106
C/G 0.18 0.207 0.013
A/G 0.17 0.157 0.017
T/G 0.18 0.187 0.0030
C/T 0.17 0.113 0.076
A/G 0.42 0.588 3.9 1020
G/A 0.16 0.330 32.4 107
A/G 0.95 1.170 2.7 1017
0.27 1.2 1061
1.19 2.2 1077
tide polymorphism.
hted sum of all risk alleles, where weights were defined as the beta
and coded allele, where the coded allele is associated later ANM.
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ANM (Table 1) but not associated with POAG (Table 2). 4.8% to 6%.25 Finally, considering POAG participants with
TABLE 2. Age at natural menopause single nucleotide polymorphisms in relation to primary open-angle glaucoma in the National Eye
Institute Glaucoma Human Genetics Collaboration Heritable Overall Operational Database (2,160 cases and 29,111 controls)
SNP chr Gene A0/A1 OR 95% CI P
SNP analysis
rs4246511 1 RHBDL2 T/C 1.04 (0.92,1.12) 0.42
rs1635501 1 EXO1 T/C 1.02 (0.92,1.10) 0.65
rs2303369 2 FNDC4 C/T 1.03 (0.93,1.11) 0.49
rs10183486 2 TLK1 C/T 0.95 (0.89,1.07) 0.24
rs4693089 4 HELQ G/A 1.01 (0.92,1.10) 0.77
rs890835 5 RNF44 A/C 1.06 (0.89,1.17) 0.40
rs365132 5 UIMC1 T/G 1.01 (0.92,1.10) 0.81
rs2153157 6 SYCP2L A/G 1.02 (0.93,1.10) 0.61
rs2517388 8 ASH2L G/T 1.03 (0.90,1.14) 0.66
rs12294104 11 near MPPED2 C11orf46 T/C 0.96 (0.87,1.11) 0.50
rs2277339 12 PRIM1 T/G 1.02 (0.86,1.18) 0.80
rs3736830 13 KPNA3 C/G 0.99 (0.88,1.12) 0.91
rs4886238 13 TDRD3 A/G 1.06 (0.93,1.13) 0.20
rs2307449 15 POLG T/G 0.98 (0.91,1.09) 0.65
rs10852344 16 near TNFRSF17 RUNDC2A, GSPT1 C/T 1.01 (0.92,1.10) 0.80
rs11668344 19 TMEM150B A/G 1.00 (0.91,1.10) 0.99
rs12461110 19 NLRP11 G/A 0.98 (0.90,1.09) 0.64
rs16991615 20 MCM8 A/G 1.11 (0.87,1.25) 0.27
GRS-based analysisa
GRS 1.013 (0.990, 1.036) 0.28
wGRS 1.002 (0.998, 1.007) 0.28
ANM, age at natural menopause; CI, confidence interval; GRS, Genetic Risk Score; OR, odds ratio; SNP, single nucleotide polymorphism.
aGRS corresponds to the sum of all risk alleles. wGRS corresponds to the weighted sum of all risk alleles, where weights were defined as the beta
coefficient of each SNP from Stolk et al.19 A0/A1 corresponds to the reference and coded allele, where the coded allele is associated later ANM.
PASQUALE ET ALEpidemiologic research supports the notion that declining
estrogen levels are important in POAG pathogenesis.2-12 Our
work suggests that for POAG, genetic20 and nongenetic
exposures influencing estrogen levels5,9 may be more import-
ant than gene-based DNA repair mechanisms that may be
more critical for other traits related to ANM such as breast
cancer,25 where positive regulation of cell growth is observed.
17-b estradiol is present in human trabecular meshwork
cells33 that contribute to intraocular pressure generation and
estrogen receptors are present on retinal ganglion cells34
that are selectively targeted for degeneration in POAG.
Thus estrogenic input could be responsible for the lower
IOP seen after estrogen replacement in postmenopausal
women12 and the neuroprotective effects of estrogen
observed in animal models of glaucoma.35,36 The definitive
null association between ANM gene variants and POAG is
critically important because it suggests these biomarkers,
although related to ANM, are not viable targets to reduce
the burden of POAG.
Although assembling genes into a panel serves to dis-
tinguish between true and false positive associations, in our
instance no single gene in the panel achieved even nominal
significance for association with POAG (Table 2). Even when
we considered a larger 44-member ANM genetic panel in
relation to POAG, our results were unequivocally null
(Supplemental Table 2, Supplemental Digital Content 2,
http://links.lww.com/MENO/A181), perhaps because the
larger panel did not materially expand the biological pathway
governing ANM much beyond DNA processing.25 Further-
more, the expanded panel only increased the variance in
reported ANM explained by common gene variants from
154 Menopause, Vol. 24, No. 2, 2017either low or extremely high ANM genetic risk scores did not
yield significant results. The difference in actual ANM was,
however, relatively small for those at the extremes of the
genetic risk score—women in the 5th percentile of the GRS
had a mean ANM of 49 years, whereas those in the 95th
percentile had a mean ANM of 50.5 years. Thus, although the
genetic risk score is significantly predictive of ANM, even the
extremes of this score may not be able to capture those with
extreme actual ANM where associations with POAG have
been observed. In the Rotterdam study, for example,7 the
significant association with greater POAG risk was with early
menopause (age <45 y) versus after age 50 years, which
represented a difference of approximately 5 years in ANM.
Although the discovery set for ANM genetic biomarkers was
large (n¼ 38,968),19 even larger samples may be needed to
discover missing heritability for ANM. There are likely
hundreds of common genetic biomarkers that contribute to
ANM and it may be worth re-examining the relation between
genetic markers for ANM and POAG at a later date when
more of these markers are known.
This study has some limitations. The findings are restricted
to Caucasians and may not be applicable to other ethnic
groups, as ANM does vary by ethnicity.37 Although the
genetic panel for ANM explains only a small percentage of
the variance in this trait, a larger panel explaining a greater
percent of the variance was also not associated with POAG
(Supplemental Table 2, Supplemental Digital Content 2,
http://links.lww.com/MENO/A181). Furthermore, we pre-
viously showed that a genetic panel directly related to estro-
gen metabolism was associated with POAG in women but not
in men.20 Finally, we did not account for other factors that
 2016 The Author(s)
might influence ANM such as smoking, body mass index, age Financial disclosure/conflicts of interest: H.A., J.N.C.B., S.L.,
MENOPAUSE GENETIC RISK SCORE AND GLAUCOMAat menarche, parity, and oral contraceptive use.37,38CONCLUSIONS
Overall, although several attributes of female reproductive
health are related to POAG, existing ANM gene variants,
either individually or collectively are not related to glaucoma
risk, indicating that genetic determinants of ANM are unlikely
to explain the previously reported association between the
two phenotypes.
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